The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
How are market drivers shaping the future growth trajectory of the cancer immunotherapy drug discovery outsourcing industry?
The high cost of research and development is expected to propel the growth of the cancer immunotherapy drug discovery outsourcing market going forward. The high cost research and development is primarily due to the need for specialized expertise, expensive equipment, and the inherent risks involved in innovation. Outsourcing drug discovery activity leverages economies of scale offered by contract research organizations (CROs), enabling smaller biotech firms and startups to optimize their R&D budgets and allocate resources more efficiently, enhancing cost-effectiveness. For instance, in June 2023, according to the European Federation of Pharmaceutical Industries and Associations (EFPIA), a European trade association representing the pharmaceutical industry, the total pharmaceutical R&D expenditure in Europe accounted for $49,500 million (€44,500 million) in 2022, an increase of approximately 6.45% from $46,500 million (€42,533 million) in 2021. Therefore, the high cost of in-house research and development is driving the growth of the cancer immunotherapy drug discovery outsourcing market.
Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=15528&type=smp
What is the estimated market size of the cancer immunotherapy drug discovery outsourcing sector by 2029, based on current forecasts?
The cancer immunotherapy drug discovery outsourcing market size has grown rapidly in recent years. It will grow from $1.5 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing cases of adverse drug reactions, increasing demand for comprehensive genomic testing, increasing global incidence of cancer, a growing need for targeted therapy, and a growing number of clinical trials.
The cancer immunotherapy drug discovery outsourcing market size is expected to see rapid growth in the next few years. It will grow to $2.57 billion in 2029 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to the rising importance of personalized medicine, increasing diagnostic tests, increasing focus on personalized cancer therapy, increasing healthcare expenditure, and increasing cancer incidence and awareness. Major trends in the forecast period include advancements in diagnostic technologies, next-generation sequencing (NGS), integration of artificial intelligence (AI), liquid biopsy technologies, the development of point-of-care companion diagnostic devices, and innovative testing technologies.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=15528&type=smp
#Who are the top players in the cancer immunotherapy drug discovery outsourcing market?
Major companies operating in the cancer immunotherapy drug discovery outsourcing market are Thermo Fisher Scientific Inc., Danaher Corporation, Laboratory Corporation of America Holdings (LabCorp), Eurofins Scientific SE, WuXi AppTec Co Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Evotec SE, Shanghai ChemPartner Co. Ltd., Aragen Life Sciences Limited, GenScript Biotech Corporation, BGI Genomics Co. Ltd., NeoGenomics Laboratories Inc., ARUP Laboratories, Syngene International Limited, BioDuro-Sundia, Ambry Genetics Corporation, Selvita, Crown Bioscience International, CENTOGENE N.V., Jubilant Biosys, Oncodesign Services, Icagen Inc., Reaction Biology Corporation, ChemBridge Corporation
#What are the major trends in the cancer immunotherapy drug discovery outsourcing market?
Major companies operating in the cancer immunotherapy drug discovery outsourcing market are adopting a strategic partnership approach to support the production of cancer drugs and gain a competitive advantage. A strategic partnership typically refers to a collaborative relationship between two or more organizations where they combine their resources, expertise, and efforts to achieve common goals or objectives. For instance, in February 2022, Ono Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, and Bristol-Myers Squibb, a US-based biopharmaceutical company, entered into an outsourcing agreement with Prime Research Institute for Medical Research, Inc., a Japan-based research institute, for a collaborative clinical research project focused on gastric cancer patients treated with Opdivo (nivolumab) in combination with chemotherapy. This industry-sponsored initiative involves a large-scale, multi-institutional study utilizing PRiME-R’s data input support system called CyberOncology, which facilitates the standardization, structuring, management, and integration of real-world data in routine cancer clinical practice. This clinical research, utilizing CyberOncology, evaluates Opdivo combined with chemotherapy for untreated advanced or recurrent gastric cancer. It involves about 30 medical institutions nationwide and aims to streamline data input, enhance data accuracy, and expedite analysis.
Which geography holds the highest cancer immunotherapy drug discovery outsourcing market share?
North America was the largest region in the cancer immunotherapy drug discovery outsourcing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy drug discovery outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
How do different segments contribute to the overall expansion of the cancer immunotherapy drug discovery outsourcing market?
The cancer immunotherapy drug discovery outsourcing market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies And Cancer Vaccines, Other Drug Types
2) By Service Type: Target Identification And Validation, Lead Screening And Characterization, Cell-Based Assays
3) By Therapeutic Area: Lung Cancer, Breast Cancer, Melanoma, Other Therapeutic Areas
Subsegments:
1) By Monoclonal Antibodies: Checkpoint Inhibitors, Therapeutic Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
2) By Immunomodulators: Cytokines, Immune Checkpoint Modulators, Toll-Like Receptor Agonists, Immune Adjuvants
3) By Oncolytic Viral Therapies And Cancer Vaccines: Oncolytic Virus-Based Therapies, Cancer Vaccines, Viral Vectors For Immunotherapy
4) By Other Drug Types: Adoptive Cell Therapy, Immune Cell Modulators, Small Molecule Immune Modulators, Gene Editing And Immunotherapy
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15528
What defines the structure and scope of the cancer immunotherapy drug discovery outsourcing market?
Cancer immunotherapy drug discovery outsourcing is a specialized service model in the pharmaceutical and biotech sectors. It entails delegating aspects of cancer immunotherapy drug development to external service providers, typically contract research organizations (CROs) or contract development and manufacturing organizations (CDMOs) to speeds up innovation by leveraging external expertise and resources, letting pharmaceutical companies focus on core activities.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
